Stifel analyst Stephen Willey raised the firm’s price target on Zymeworks (ZYME) to $30 from $28 and keeps a Buy rating on the shares. The firm believes the recent ENA 2025 presentation of preliminary ZW191 dose-escalation data demonstrating encouraging efficacy and a widened therapeutics not previously seen with TOP01i-equipped ADCs should appropriately increase investor enthusiasm for the now-enrolling Phase 1 does-escalation trial evaluation ZW251 in a tumor type, the analyst tells investors in a research note.
Meet Your ETF AI Analyst
- Discover how TipRanks' ETF AI Analyst can help you make smarter investment decisions
- Explore ETFs TipRanks' users love and see what insights the ETF AI Analyst reveals about the ones you follow.
Published first on TheFly – the ultimate source for real-time, market-moving breaking financial news. Try Now>>
Read More on ZYME:
- Zymeworks’ Strong Q3 Performance and Promising Pipeline Drive Buy Rating
- Zymeworks Reports Q3 2025 Progress and Financials
- Zymeworks: Promising Advancements and Financial Stability Support Buy Rating
- Zymeworks reports Q3 EPS (26c), consensus (32c)
- Zymeworks Reports Strong Q3 2025 Financial Performance